Iovance granted 139,930 stock options to 17 new non-executive employees on July 16, 2026 under its 2021 Inducement Plan at an exercise price of $4.66 per share.
Iovance Biotherapeutics disclosed employment-related inducement grants under Nasdaq Listing Rule 5635(c)(4), detailing stock option awards covering 139,930 shares for 17 new, non-executive employees approved on July 16, 2026. The options were granted under the company’s Amended and Restated 2021 Inducement Plan at an exercise price of $4.66 per share, equal to the stock’s closing price on the grant date, and vest over three years subject to continued employment.